media – Page 4 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Under the vaccine price war, the performance of the leading influenza vaccine company Hualan Vaccine in 2024 has stalled

Recently, Hualan Vaccine (301207.SZ), a domestic influenza vaccine manufacturer, released its 2024 annual report: the company achieved revenue of 1.128 billion yuan, a year-on-year decrease of 53.21%; net profit attributable to the parent company was 206 million yuan, a year-on-year decrease of 76.10%; net profit attributable to the parent company after deducting non-recurring items was 120 million yuan, a year-on-year decrease of 84.12%. Regarding the rapid decline in performance this time, Hualan Vaccine pointed out that due to multiple factors such as the reduction in influenza vaccine prices, fluctuations in vaccination rates among the public, changes in market demand and declining sales, the company’s business development and profitability were under great pressure, resulting in a significant decline in performance in 2024. Quadrivalent influenza vaccine is in full competition, and the price war has begun It is worth noting that Hualan Vaccine’s main sales product is influenza vaccine, and its product ...
- Source: drugdu
- 72
- April 3, 2025
Winning the first generic product! Huabang Pharmaceutical enters the market with strength

Recently, the topical drug calcipotriol-betamethasone ointment for the treatment of psoriasis developed by Chongqing Huabang Pharmaceutical was approved for marketing by the State Food and Drug Administration, becoming the first generic drug of calcipotriol-betamethasone ointment in China . Behind this is the story of how Huabang Pharmaceutical’s “China Solution” took ten years of research and development to finally break the 16-year market monopoly of original drugs in China. Ten Years of Breakthrough of the “China Solution” Calcipotriol-betamethasone ointment was originally developed by LEO Pharma and first launched in Denmark in March 2001. It was subsequently launched in many European countries and the United States (2006) and in China in September 2008 (trade name: Defubao). This product is a compound preparation of calcipotriol and betamethasone dipropionate. It inhibits the proliferation of keratinocytes through the vitamin D analog calcipotriol, combined with the anti-inflammatory, antipruritic, vasoconstrictive and immunosuppressive effects of betamethasone dipropionate, making ...
- Source: drugdu
- 70
- April 3, 2025
Entering a new era, medical device giants have reached a latest cooperation agreement

According to foreign media reports, medical device giant Solventum recently announced a strategic partnership with digital dental company SprintRay to jointly promote the application of disruptive 3D printing technology in the field of dental restoration. It is reported that this cooperation aims to meet the daily diagnosis and treatment needs of dentists for permanent restorations such as crown restorations, embedded restorations, and high embedded restorations through chair side 3D printing technology. The related research and commercialization process will focus on the full process solution for completing the restoration treatment on the same day. According to the announcement, the dental solutions division of Shuwannuo will integrate its cutting-edge materials science and big data analysis capabilities, integrating its subsidiary Filtek Easy Matching Universal Restoration Materials, Filtek Matrix Systems, Scotchbond Universal Adhesives, and RelyX ™ Core products such as self-adhesive resin cement. SprintRay will provide an end-to-end 3D printing ecosystem for chair side ...
- Source: drugdu
- 51
- April 2, 2025
Another ‘innovative medical device’ approved for market launch

Recently, the National Medical Products Administration approved the registration application for the innovative product “Disposable Pressure Monitoring Radiofrequency Ablation Catheter” of Hunan Aptech Medical Equipment Co., Ltd. (hereinafter referred to as Aptech Medical). Another flagship product has been approved Established in 2006, Aptech Medical is a wholly-owned subsidiary of Shenzhen Huitai Medical Equipment Co., Ltd. (hereinafter referred to as Huitai Medical). Epert Medical is a high-tech enterprise specializing in the research, development, production, and sales of cardiac electrophysiology and interventional medical devices. Currently, it has formed a business layout with complete coronary access and cardiac electrophysiology medical devices as the main focus, and peripheral vascular and neural interventional medical devices as the key development direction. It is understood that the disposable pressure monitoring radiofrequency ablation catheter from Epert Medical is composed of a head end, a tube body, a handle, a cable, a saline connector, and an optoelectronic hybrid plug. ...
- Source: drugdu
- 53
- April 2, 2025
Cultivate “Innovation Skills” and Cultivate “Conscience Seedlings”

After 14 years of deep cultivation in the vaccine track, AIM Vaccine’s innovative achievements have gradually blossomed, and it has embarked on a small, beautiful, refined and specialized road of special vaccine research and development in the global market. In March this year, the company’s mRNA herpes zoster vaccine obtained clinical trial approval from the U.S. Food and Drug Administration (FDA); mRNA RSV (respiratory syncytial virus) vaccine was approved for clinical trials in the United States in February; by the end of 2024, the company’s two blockbuster single-product vaccines will iterate serum-free rabies vaccine and 13-valent pneumococcal conjugate vaccine, obtain corresponding production licenses, and submit a listing registration application. “For traditional products, ‘the last one standing will win’, and for high-end single products, ‘all will prosper together’. We firmly believe that focusing on the research and development of iterative vaccine series is the real growth engine in the future, which ...
- Source: drugdu
- 54
- April 2, 2025
The “magnetic attraction” of the Chinese market is strong, and foreign companies are investing in China

AstraZeneca announced that it will establish its sixth global strategic R&D center in Beijing, BASF is building an integrated production base with a total investment of approximately 10 billion euros in Zhanjiang, Guangdong, and Shanghai Pudong has welcomed 13 regional headquarters of multinational companies and 4 foreign-funded R&D centers… Recently, foreign executives have visited China intensively, major projects have been frequently implemented, and policies to stabilize foreign investment have continued to increase. China’s “magnetic attraction” to attract foreign investment is strong. Many heads of foreign-funded enterprises said that China’s super-large market, complete production and supply chain system and scientific and technological innovation capabilities are huge opportunities. Investing in China is to go hand in hand with opportunities. They are willing to continue to expand investment in China and open up innovative cooperation space. Foreign-funded enterprises have cast their votes of confidence with “real money”, and cutting-edge innovation fields such as ...
- Source: drugdu
- 44
- April 2, 2025
The sampling results failed, and the core products of Weiming Pharmaceutical were suspended from purchase in many places

Less than a year after the centralized procurement results were implemented, the human interferon α2b spray produced by Tianjin Weiming Biopharmaceutical Co., Ltd. (hereinafter referred to as “Tianjin Weiming”) was suspended from purchase in some areas. On March 26, the Tibet Autonomous Region Medical Security Bureau (hereinafter referred to as “Tibet Medical Security Bureau”) issued the “Notice on Suspending the Purchase of Human Interferon α2b Spray of Tianjin Weiming Biopharmaceutical Co., Ltd.” The content shows that the drug supervision department recently conducted a random inspection of the α2b spray produced by Tianjin Weiming, and the test results were “biological activity does not meet the regulations.” In accordance with relevant requirements, it is recommended that medical institutions in the region suspend the purchase of human interferon α2b spray produced by Tianjin Weiming, and the selected enterprises are sealed and recalled, and the resumption time will be notified separately. Based on this, ...
- Source: drugdu
- 46
- April 2, 2025
innovation-driven construction of a recovery curve, and new industry layout opens up growth space

Haier Bio (688139.SH) released its 2024 annual performance report. The company achieved a total operating income of 2.284 billion yuan for the whole year, and resumed positive growth. After the growth rate of operating income turned positive year-on-year in the third quarter, the growth rate in the fourth quarter further increased to 10.40%, and the business recovery trend was significant. It is worth noting that in 2024, the company’s new industry performed well, with an annual growth rate of 21.25%, and the proportion of main operating income further increased to 45.47%, an increase of 7.93 percentage points year-on-year. The results of the strategic transformation have been fully verified, and the company’s “second growth curve” has gradually emerged. Data shows that Haier Bio’s ability to rely on technological innovation and AI deep empowerment to continuously iterate digital scene solutions has entered the period of achievement transformation. From the perspective of business ...
- Source: drugdu
- 47
- April 2, 2025
【EXPERT Q&A】What is the difference between siRNA and shRNA in RNA interference technology?

Drugdu.com expert’s response: I. Molecular Structure and Synthesis siRNA: A chemically synthesized or in vitrotranscribed double-stranded RNA molecule, comprising 21–23 base pairs with 2–3 nucleotide overhangs at both ends. Directly delivered to the cytoplasm, where it binds to the RNA-induced silencing complex (RISC) to guide targeted mRNA cleavage. Rapid onset of action (within hours) but has a shorter half-life (typically hours to two days), requiring repeated dosing. Recent advancements in chemical modifications (e.g., 2′-O-methylation, phosphorothioate bonds) have extended stability to ~1 week. Systemic delivery still relies on lipid nanoparticles or GalNAc conjugation for tissue targeting. shRNA: A single-stranded RNA delivered via plasmid or viral vectors. Its hairpin structure is transcribed by RNA polymerase III (Pol III) in the nucleus and processed by Dicer enzyme into functional siRNA. Delayed onset (24–72 hours) but offers sustained gene silencing for weeks to months. Ideal for stable gene knockdown models (e.g., neurodegenerative disease studies using ...
- Source: drugdu
- 64
- April 2, 2025
The first domestic case! Hair transplant surgery robot successfully completed commercial landing

Recently, the first hair transplant robot surgery in China was fully operational at the Run Run Shaw International Medical Center, successfully completing a hair transplant surgery for a 45 year old patient. The success of this surgery has a milestone dual significance: on the one hand, Run Run Shaw International Medical Center’s full process medical care has opened a new era of intelligent and precise hair transplant surgery; On the other hand, as the first domestically produced hair transplant robot to achieve commercialization in China, “Shuzhidao” has successfully broken the foreign technology monopoly and fully demonstrated the innovation strength of Chinese medical technology enterprises. 01. Customized human-machine collaboration solution, reshaping the gold standard of surgery The patient recently sought a hair transplantation solution at the Run Run Shaw International Medical Center. After a series of comprehensive and detailed preoperative examinations and evaluations, Dr. Zhou Qiang, a senior expert in the ...
- Source: drugdu
- 60
- April 1, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.